Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories

View ORCID ProfileYang Liu, Christian Morgenstern, James Kelly, View ORCID ProfileRachel Lowe, CMMID COVID-19 Working Group, View ORCID ProfileMark Jit
doi: https://doi.org/10.1101/2020.08.11.20172643
Yang Liu
1Centre for Mathematical Modelling of Infectious Disease, London School of Hygiene & Tropical Medicine, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yang Liu
Christian Morgenstern
2Informed Portfolio Management, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Kelly
2Informed Portfolio Management, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachel Lowe
1Centre for Mathematical Modelling of Infectious Disease, London School of Hygiene & Tropical Medicine, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rachel Lowe
Mark Jit
1Centre for Mathematical Modelling of Infectious Disease, London School of Hygiene & Tropical Medicine, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mark Jit
  • For correspondence: mark.jit{at}lshtm.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Introduction Non-pharmaceutical interventions (NPIs) are used to reduce transmission of SARS coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19). However, empirical evidence of the effectiveness of specific NPIs has been inconsistent. We assessed the effectiveness of NPIs around internal containment and closure, international travel restrictions, economic measures, and health system actions on SARS-CoV-2 transmission in 130 countries and territories.

Methods We used panel (longitudinal) regression to estimate the effectiveness of 13 categories of NPIs in reducing SARS-CoV-2 transmission with data from January - June 2020. First, we examined the temporal association between NPIs using hierarchical cluster analyses. We then regressed the time-varying reproduction number (Rt) of COVID-19 against different NPIs. We examined different model specifications to account for the temporal lag between NPIs and changes in Rt, levels of NPI intensity, time-varying changes in NPI effect and variable selection criteria. Results were interpreted taking into account both the range of model specifications and temporal clustering of NPIs.

Results There was strong evidence for an association between two NPIs (school closure, internal movement restrictions) and reduced Rt. Another three NPIs (workplace closure, income support and debt/contract relief) had strong evidence of effectiveness when ignoring their level of intensity, while two NPIs (public events cancellation, restriction on gatherings) had strong evidence of their effectiveness only when evaluating their implementation at maximum capacity (e.g., restrictions on 1000+ people gathering were not effective, restrictions on <10 people gathering was). Evidence supporting the effectiveness of the remaining NPIs (stay-at-home requirements, public information campaigns, public transport closure, international travel controls, testing, contact tracing) was inconsistent and inconclusive. We found temporal clustering between many of the NPIs.

Conclusion Understanding the impact that specific NPIs have had on SARS-CoV-2 transmission is complicated by temporal clustering, time-dependent variation in effects and differences in NPI intensity. However, the effectiveness of school closure and internal movement restrictions appears robust across different model specifications taking into account these effects, with some evidence that other NPIs may also be effective under particular conditions. This provides empirical evidence for the potential effectiveness of many although not all the actions policy-makers are taking to respond to the COVID-19 pandemic.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

YL and MJ are funded by the National Institute of Health Research (UK)(16/137/109), the Bill & Melinda Gates Foundation (INV-003174), and the European Commission (101003688). This research was partly funded by the National Institute for Health Research (NIHR) (16/137/109) using UK aid from the UK Government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care. This research is partly funded by the Bill & Melinda Gates Foundation (INV-003174). The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Bill & Melinda Gates Foundation. YL is also supported by the UK Medical Research Council (MC_PC_19065). CM and JK are employed by IPM Informed Portfolio Management. IPM is appreciative of the contributions of its employees above and beyond the scope of their work, their dedication to the community and the world as a whole. The views expressed herein are made in a personal capacity and are not those necessarily made, sponsored, affiliated or endorsed by IPM. RL is a UK Royal Society Dorothy Hodgkin Fellow.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

London School of Hygiene and Tropical Medicine

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • The following authors were part of the Centre for Mathematical Modelling of Infectious Disease COVID-19 Working Group, who contributed to providing valuable comments/ feedback to this work: James Munday; C Julian Villabona-Arenas; Hamish Gibbs; Carl A B Pearson; Kiesha Prem; Quentin J Leclerc; Sophie R Meakin; W John Edmunds; Christopher I Jarvis; Ammy Gimma; Sebastian Funk; Matthew Quaife; Timothy W Russell; Jon C Emory; Sam Abbott; Joel Hellewell; Damien C Tully; Rein M G J Houben; Kathleen O’Reilly; Georgia R Gore-Langton; Adam J Kucharski; Megan Auzenbergs; Billy J Quilty; Thibaut Jombart; Alicia Rosello; Oliver Brady; Katherine E. Atkins; Kevin van Zandvoort; James W Rudge; Akira Endo; Kaja Abbas; Fiona Yueqian Sun; Simon R Procter; Samuel Clifford; Anna M Foss; Nicholas G. Davies; Yung-Wai Desmond Chan; Charlie Diamond; Rosanna C Barnard; Rosalind M Eggo; Arminder K Deol; Emily S Nightingale; David Simons; Katharine Sherratt; Graham Medley; Stéphane Hué; Gwenan M Knight; Stefan Flasche; Nikos I Bosse; Petra Klepac

Data Availability

All data is availability through database described in this manuscript. Code used can be found here [https://github.com/yangclaraliu/COVID19_NPIs_vs_Rt].

https://github.com/yangclaraliu/COVID19_NPIs_vs_Rt

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted August 12, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories
Yang Liu, Christian Morgenstern, James Kelly, Rachel Lowe, CMMID COVID-19 Working Group, Mark Jit
medRxiv 2020.08.11.20172643; doi: https://doi.org/10.1101/2020.08.11.20172643
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories
Yang Liu, Christian Morgenstern, James Kelly, Rachel Lowe, CMMID COVID-19 Working Group, Mark Jit
medRxiv 2020.08.11.20172643; doi: https://doi.org/10.1101/2020.08.11.20172643

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Health Policy
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)